KINDAI UNIVERSITY


*A space between the first name and last name, please enter

OTORI Toru

Profile

FacultyDepartment of Pharmacy / Graduate School of Medicine
PositionAssociate Professor
Degree
Commentator Guidehttps://www.kindai.ac.jp/meikan/802-ootori-tooru.html
URL
Mail
Last Updated :2020/08/10

Education and Career

Education

  •   1986 04  - 1990 03 , Kyoto Pharmaceutical University, Pharmaceutical Sciences

Academic & Professional Experience

  •   2011 04 ,  - 現在, Faculty of Pharmacy, Kindai University
  •   2006 04 ,  - 2011 03 , Faculty of Pharmacy, Kindai University

Research Activities

Published Papers

  • Comparison of the perception between pharmacy students and practicing pharmacists in the acquisition of physical assessment skills, Toru Otori, Tomomi Inoue, Koichi Hosomi, William Figoni, Manabu Kitakoji, Hiroko Hachiken, Hiroyuki Nakagawa, Keiko Takashima, Hisami Kondo, Tsugumi Takada, Kenji Matsuyama, Shozo Nishida, Japn. J. Soc. Pharm, Japn. J. Soc. Pharm, 37(2), 127 - 133, 2018 , Refereed
  • Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma, Yoshiaki Yamamoto∗, Ryouichi Tsunedomi, Yusuke Fujita, Toru Otori, Yoshihisa Kawai, Ryo Inoue, Hiroshi Hirata, Hiroaki Matsumoto, Tomoyuki Shimabukuro, Rajvir Dahiya, Hideyasu Matsuyama, Oncotarget, Oncotarget, 9(24), 17160 - 17170, 2018 , Refereed
  • Stability Evaluations of Montelukast Tablets Under Conditions of Single Dose Packaging, Masayoshi Matsuura, Toru Otori, Atsushi Kawase, Hiroaki Shimada, Hideyuki Nakanishi, Masahiro Iwaki, Intl. J. Pharm.Tech., Intl. J. Pharm.Tech., 9(4), 31079 - 31087, 2017 , Refereed
  • Survey of patient comprehension for home medical care and the performance of the pharmacist., Keiko Takashima, Yasuhiro Yoshikawa, Manabu Kitakouji, Takashi Okumura, Hiroaki Tanabe, Kenzo Okumura, Toru Otori, Kenji Matsuyama, Norio Oda, 4(1), 38 - 45, 2017 , Refereed
  • Survey on customer satisfaction for evaluation and improvement of physical assessment practical training seminar for Pharmacists., Toru Otori, Tomomi Inoue, Koichi Hosomi, Hiroyuki Nakagawa, Keiko Takashima, Hisami Kondo, Tsugumi Takada, Eiji Ito, Tkashi Nakayama, Tetsuyuki Wada, Shunji Ishiwata, Yoshinori Funakami, Shinya Nakamura, Yoshie Kubota, Atsushi Hiraide, Kenji Matsuyama, Shozo Nishida, 35(2), 94 - 1001, 2017 , Refereed
  • Fluoropyrimidines S-1 and Capecitabine may Prolong International Normalized Ratios of Prothrombin Time by 3-Fold in Cancer Patients Receiving Warfarin, Masayuki Ikenishi, Akiko Kuroda, Haruhiko Tsukazaki, Masahiko Nakao, Masashi Takeuchi, Yuji Konishi, Toshiyuki Matsuda, Tohru Ohtori, Kenji Matsuyama, Mitsutaka Takada, Hiroki Satoh, Yasufumi Sawada Mutsuaki, Japanese Journal of Drug Information, Japanese Journal of Drug Information, 18(3), 172 - 178, 2016 , Refereed
  • A Study on Drug Interaction between Warfarin and Capecitabine with Special Reference to the Co-administered Term or the Discontinuation Term of Capecitabine, Masayuki Ikenishi, Mutsuaki Ueda, Akiko Kuroda, Haruhiko Tsukazaki, Masahiko Nakao, Masashi Takeuchi, Yuji Konishi, Toshiyuki Matsuda, William Figoni, Toru Otori, Kenji Matsuyama, Hiroki Satoh, Yasufumi Sawada, Eitaro Nakatsuka, Jap. J. Canc. Chemo, Jap. J. Canc. Chemo, 42(7), 833 - 839, 2015 , Refereed
  • An evaluation of usage and utilization of generic drugs by clinical medicine departments using a questionnaire of chain community pharmacies in Japan, Noriaki Nagai, Yusei Kim, Sumio Matzno, Kenji Matsuyama, Toru Otori, 16(3), 137 - 172, 2014 , Refereed
  • Training of pharmacists in the assessment of vital signs using human subjects for the purpose of better pharmacist-patient communication, Otori T, Murakami E, Matsuyama K, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 132, 381 - 386, 2012 , Refereed
  • Application of Near-infrared Spectroscopy for Evaluating Generic Formulations of the Drug Losartan, Toru Otori, Takuya Shimomura, Noraki Nagai, William Figoni, Kenji Matsuyama, Intl. J. Pharm.Tech, Intl. J. Pharm.Tech, 7(2), 9015 - 9027, Refereed
  • APPLICATION OF NEAR-INFRARED SPECTROSCOPY FOR EVALUATING GENERIC FORMULATIONS OF THE DRUG AMLODIPINE, Toru Otori, International Journal of Pharmacy & Technology, International Journal of Pharmacy & Technology, 5(3), 5783 - 5792, Refereed
  • Development of hemiacetal esterified levofloxacin to prevent chelation with metal-containing drugs, Toru Otori, Sumio Matzno, Atushi Kawase, Masahiro Iwaki, Tetsutaro Kimachi, Keiji Nishiwaki, William C. Figoni, Ryuta Tominaga, Mai Asahide, Mayumi Nishikata, Yoshikazu Ishii, Kenji Matsuyama, JOURNAL OF PHARMACY AND PHARMACOLOGY, JOURNAL OF PHARMACY AND PHARMACOLOGY, 68(12), 1527 - 1534, Dec. 2016 , Refereed
    Summary:ObjectivesTo avoid the chelate formation between levofloxacin (LVFX) and aluminium hydroxide in gastrointestinal tract, an ethoxycarbonyl 1-ethyl hemiacetal ester of levofloxacin (LVFX-EHE) was synthesised as a prodrug. MethodsThe effects of aluminium hydroxide on the bioavailability of LVFX following oral administration of LVFX-EHE were investigated in rats. Furthermore, the effects of aluminium hydroxide on small intestinal absorption of LVFX and LVFX-EHE when subjected to a hydrolysis experiment using in situ everted gut sac were investigated, and the minimal inhibitory concentrations (MICs) of LVFX and LVFX-EHE for various intestinal bacteria were measured. Key findingsWhen LVFX-EHE was co-administered with and without aluminium hydroxide, the AUC(0-4 h) values of LVFX hydrolysed from LVFX-EHE were similar to that of LVFX alone. In everted gut sac experiments, LVFX-EHE was efficiently absorbed even in the presence of aluminium ions after 1 h of incubation, whereas the absorption of LVFX decreased significantly in the presence of aluminium ions. MIC values of LVFX-EHE were far higher than LVFX. ConclusionsThis study suggests the benefit of ethoxycarbonyl 1-ethyl hemiacetal esterification of the carboxyl group of new quinolone as a prodrug which is able to avoid chelate formation.
  • Effects of duration of phenytoin administration on mRNA expression of cytochrome P450 and P-glycoprotein in the liver and small intestine of rats, Atsushi Kawase, Hiroyuki Tanaka, Toru Otori, Kenji Matsuyama, Masahiro Iwaki, ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 11(5), 662 - 667, Oct. 2016 , Refereed
    Summary:Phenytoin (5,5-diphenylhydantoin; DPH) induces expression of cytochromes P450 (CYPs). Interactions between DPH and tacrolimus suggested that the persistence of CYP induction after discontinuation of DPH is dependent on the history of administration and dosing period of DPH. However, the relationship between the duration of DPH administration and expression of CYPs in the liver and small intestine of rats is not known. Alterations in levels of P-glycoprotein (P-gp; MDR1; ABCB1) as well as CYPs cause drug interactions in the small intestine. We examined the effects of the duration of DPH administration on expression of CYPs and P-gp in the liver and small intestine of rats. Rats were treated with DPH (100 mg/kg, peroral (p.o.) twice a day (b.d.)) for 2, 4, 8, and 16 d. mRNA levels of CYPs and P-gp were examined using the total RNA extracted from the liver and duodenum 2 h and 24 h after the final administration of DPH. CYP3A activities were determined using microsomes. DPH administration for 2 d and 4 d markedly increased mRNA levels of CYPs such as CYP3A1, CYP3A2, CYP2B1, and CYP2B2 in the liver. A relatively long duration of DPH administration (8 d and 16 d) resulted in abolition of the induction of hepatic CYP but increased CYP3A activities were maintained. These results suggest that the duration of DPH administration could be an important determinant of hepatic CYP induction. (C) 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V.
  • Pharmacokinetic model analysis of the interaction between phenytoin and capecitabine, Shohei Miyazaki, Hiroki Satoh, Masayuki Ikenishi, Miyuki Sakurai, Mutsuaki Ueda, Kaori Kawahara, Rie Ueda, Tohru Ohtori, Kenji Matsuyama, Akiko Miki, Satoko Hori, Eiji Fukui, Eitaro Nakatsuka, Yasufumi Sawada, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 54(9), 657 - 665, Sep. 2016 , Refereed
    Summary:Objective: Recent reports have shown an increase in serum phenytoin levels resulting in phenytoin toxicity after initiation of fluoropyrimidine chemotherapy. To prevent phenytoin intoxication, phenytoin dosage must be adjusted. We sought to develop a pharmacokinetic model of the interaction between phenytoin and capecitabine. Methods: We developed the phenytoin-apecitabine interaction model on the assumption that fluorouracil (5-FU) inhibits cytochrome P450 (CYP) 2C9 synthesis in a concentration- dependent manner. The plasma 5-FU concentration after oral administration of capecitabine was estimated using a conventional compartment model. Nonlinear pharmacokinetics of phenytoin was modeled by incorporating the Michaelis-Menten equation to represent the saturation of phenytoin metabolism. The resulting model was fitted to data from our previously-reported cases. Results: The developed phenytoincapecitabine interaction model successfully described the profiles of serum phenytoin concentration in patients who received phenytoin and capecitabine concomitantly. The 50% inhibitory 5-FU concentration for CYP2C9 synthesis and the degradation rate constant of CYP2C9 were estimated to be 0.00310 ng/mL and 0.0768 day(-1), respectively. This model and these parameters allow us to predict the appropriate phenytoin dosage schedule when capecitabine is administered concomitantly. Conclusions: This newly-developed model accurately describes changes in phenytoin concentration during concomitant capecitabine chemotherapy, and it may be clinically useful for predicting appropriate phenytoin dosage adjustments for maintaining serum phenytoin levels within the therapeutic range.
  • A Trial of the Integrated Cross-field Pharmaceutical Education in the First Year of Faculty of Pharmacy, Tomohisa Yasuhara, Naohito Kawasaki, Hideki Yagi, Eiji Itoh, Atsushi Kawase, Toru Otori, Tetsuyuki Wada, Kenji Matsuyama, Masahiro Iwaki, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 130(12), 1647 - 1653, Dec. 2010 , Refereed
    Summary:The six-year pharmacist education course has begun, and now first-year students receive clinical training. Interdisciplinary problem-solving capabilities covering chemistry, biology, molecular biology, pharmacology, pathology, and pharmacokinetics are necessary for new pharmacists. However, the conventional pharmaceutical science education was so separate from other fields that education for interdisciplinary cooperative capability was insufficient. This was especially true of elemental science courses, because they are not directly connected with clinical knowledge, and there is a problem of low student interest in those courses. As a result, students acquired only recall-level knowledge in clinical courses and their problem-solving capabilities in clinical treatment and drug development deteriorated. Therefore we offered a trial lecture aimed to help students recognize the important relationship between elemental science courses and clinical courses and increase their motivation to enroll in these courses. Specifically, the trial lecture covered cancer therapy, in reference to mechanisms of carcinogenesis, epidemiology, physiology of cancer, anticancer drugs with explanations of the mechanism of action of carcinogens, anticancer drugs, and molecular-targeted drugs from the viewpoints of organic chemistry and biochemistry by a specialized teacher. This paper reports on this experimental lecture with evaluations from students.

Conference Activities & Talks

  • Prediction of total clearance by UGT1A and ABC genes polymorphisms can predict tumor response and proteinuria in axitinib treatment for advanced renal cell carcinoma., H. Matsuvama, Y. Yamamoto, Y. Kawai, Y. Fujita, Y. Hamamoto, K. Matsuyama, T. Otori, J. Haginaka, EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 2017,   2017
  • The Implementation of the Model Core Curriculum toward Hospital Pharmacy Practice Experience,   2009 03
  • The Implementation of the Model Core Curriculum toward Pharmacy Practice Experience for 2-4 weeks,   2008 03
  • A Survey on the Students’ Attitudes toward Pharmacy Practice Experience in Kinki University,   2007 03